TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02169245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary control of protein and fiber intake at breakfast
Description: Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary control of protein and fiber intake at breakfast
Description: Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary control of protein and fiber intake at breakfast
Description: Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary control of protein and fiber intake at breakfast
Description: Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
Study: NCT00449033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy component; Cisplatin 75 mg/m\^2 IV
Study: NCT00179153

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nepro nutritional supplement
Description: oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
Study: NCT03744065

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar plexus block
Description: Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprainguinal fascia iliaca block
Description: Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
Study: NCT04738188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: Drug-eluting beads transcatheter arterial chemoembolization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cTACE
Description: Transcatheter arterial chemoembolization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting Beads
Description: Drug-eluting beads
Study: NCT01205685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: In a pill form, by mouth, once per day at 2.5 mg/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
Study: NCT04738188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Chemotherapy drug for intra-arterial infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Chemotherapy drug for intra-arterial infusion
Study: NCT01142466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (Rebif)
Description: The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
Study: NCT03648736

Intervention type: OTHER
Intervention: blood withdrawal
Description: * peripheral-venous before TASH, day 1, 2, 3, one week and one month after TASH procedure~* central-venous during TASH
Study: NCT01593774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Tablet melatonin 3 mg/day at 9 pm as intervention group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (with the same shape and taste as melatonin) at 9 pm as control group
Study: NCT02748213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Participants will receive oral Xeloda, 950 mg/m\^2 twice a day on Days 1 to 14 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
Study: NCT00449033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy component; Cisplatin 75 mg/m\^2 IV
Study: NCT00906685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Intravitreal injection of 1.25 mg bevacizumab
Study: NCT01349699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron sucrose
Description: 1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: 30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: endotoxin
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol.
Study: NCT02259296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower eGFR for AVF construction
Description: Lower eGFR patients (eGFR\<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR\<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Higher eGFR for AVF construction
Description: Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
Study: NCT01116830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: 10 mg daily orally for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Antipsychotic Therapy
Description: Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Antipsychotic Therapy
Description: Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
Study: NCT01023022

Intervention type: OTHER
Intervention: Medtronic CareLink® Network
Description: The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
Study: NCT00687128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-intensity treadmill exercise
Description: Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill exercise
Description: Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic stretching exercise
Description: Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
Study: NCT00003778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolastatin 10
Study: NCT01320514

Intervention type: DRUG
Intervention: Fibrin Sealant (Artiss)
Study: NCT02524951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-1436C
Description: Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-1436C
Description: Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
Study: NCT00906685

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham bevacizumab injection
Description: Sham intravitreal injection
Study: NCT03349710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified day
Study: NCT03349710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified day
Study: NCT02524951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-1436C
Description: Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-1436C
Description: Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-1436C
Description: Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
Study: NCT05703477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
Study: NCT00123487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 70 mg BID, indefinitely, survival study
Study: NCT03349710

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified day

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Specified dose on specified day
Study: NCT00406575

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin (rhRlx)
Description: Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
Study: NCT00123487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 140 mg QD, indefinitely, survival study
Study: NCT00406575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin (rhRlx)
Description: Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
Study: NCT00420849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
Study: NCT03269474

Intervention type: PROCEDURE
Intervention: Experimental Group
Description: Subjects with EB diagnosis
Study: NCT00420849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
Study: NCT02486471

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monsel´s Paste
Description: surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible

Intervention type: OTHER
Group type: OTHER
Intervention: Wait and see
Description: finishing examination without hemostatic intervention, awaiting spontaneous coagulation
Study: NCT02748213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
Study: NCT05809960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing support program
Description: It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
Study: NCT00538161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation strategy
Study: NCT03782584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified pilates exercise
Description: modified exercises from original pilates exercises.
Study: NCT00538161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation strategy
Study: NCT03782584

Intervention type: OTHER
Group type: OTHER
Intervention: daily life advises
Description: they will be given daily life advises to prevent neck pain
Study: NCT01699594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
Study: NCT03178357

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac rehabilitation + standard therapy
Description: Patients with HCM subjected to cardiological rehabilitation

Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy
Description: Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
Study: NCT04517721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)
Description: The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-Led Transitional Burns Rehabilitation Programme (4Cs-TBuRP)
Description: The nurse-led transitional burns rehabilitation programme (4Cs-TBuRP) is presented as an 8-week interventional programme that supports holistic care for adult burn survivors led by a specialist burn care nurse and supported by the burn care team. The intervention posits that as the adult burn survivor transitions, several physiological, psychosocial, health-related behaviour and environmental needs emerge which lead to poor quality of life. Despite this, they may be unable to return to utilise available healthcare services or have inadequate contact with rehabilitation services. To facilitate their recovery and enhance the attainment of rehabilitation outcomes, the 4Cs-TBuRP views the burn care nurse as the link between rehabilitation services and the adult burn survivor. Thus, the burn care nurse serves as the coordinator of care and actively collaborates with the burn care team and the patient/ family to ensure that continuous care is delivered in a timely manner.
Study: NCT00925158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dissector Assisted Malar Elevation
Description: Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
Study: NCT01981135

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Study: NCT01857544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Monthly 2.0mg Aflibercept Intravitreal Injection
Study: NCT04121104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched off
Description: Spinal cord stimulator is switched off for 12 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched on
Description: Spinal cord stimulator is on
Study: NCT01233817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Description: the systematic increase in resistance weights
Study: NCT00905580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Complex (placebo)
Description: Vitamin Complex 150 mg orally
Study: NCT02872064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
Study: NCT03678948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency-Based Debridement
Description: In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement